Impact of Sodium–Glucose Cotransporter 2 (SGLT2) Inhibitors on Arterial Stiffness and Vascular Aging—What Do We Know So Far? (A Narrative Review)

Adam, Cristina Andreea; Anghel, Razvan; Marcu, Dragos Traian Marius; Mitu, Ovidiu; Roca, Mihai; Mitu, Florin

doi:10.3390/life12060803

Open AccessReview

Impact of Sodium–Glucose Cotransporter 2 (SGLT2) Inhibitors on Arterial Stiffness and Vascular Aging—What Do We Know So Far? (A Narrative Review)

by

Cristina Andreea Adam

¹

,

Razvan Anghel

^1,2,

Dragos Traian Marius Marcu

^2,*,

Ovidiu Mitu

^2,3,*

,

Mihai Roca

^1,2 and

Florin Mitu

^1,2

¹

Clinical Rehabilitation Hospital, Cardiovascular Rehabilitation Clinic, Pantelimon Halipa Street nr. 14, 700661 Iaşi, Romania

²

Department of Internal Medicine, University of Medicine and Pharmacy, Grigore T. Popa, University Street nr. 16, 700115 Iaşi, Romania

³

Sf. Spiridon Clinical Emergency Hospital, Independence Boulevard nr. 1, 700111 Iasi, Romania

^*

Authors to whom correspondence should be addressed.

Life 2022, 12(6), 803; https://doi.org/10.3390/life12060803

Submission received: 1 May 2022 / Revised: 23 May 2022 / Accepted: 25 May 2022 / Published: 27 May 2022

(This article belongs to the Section Medical Research)

Download

Browse Figures

Versions Notes

Abstract

Vascular aging, early vascular aging or supernormal vascular aging are concepts used for estimating the cardiovascular risk at a certain age. From the famous line of Thomas Sydenham that “a man is as old as his arteries” to the present day, clinical studies in the field of molecular biology of the vasculature have demonstrated the active role of vascular endothelium in the onset of cardiovascular diseases. Arterial stiffness is an important cardiovascular risk factor associated with the occurrence of cardiovascular events and a high risk of morbidity and mortality, especially in the presence of diabetes. Sodium–glucose cotransporter 2 inhibitors decrease arterial stiffness and vascular resistance by decreasing endothelial cell activation, stimulating direct vasorelaxation and ameliorating endothelial dysfunction or expression of pro-atherogenic cells and molecules.

Keywords: vascular aging; arterial stiffness; SGLT2 inhibitors; early vascular aging; diabetes mellitus; cardiovascular risks

Share and Cite

MDPI and ACS Style

Adam, C.A.; Anghel, R.; Marcu, D.T.M.; Mitu, O.; Roca, M.; Mitu, F. Impact of Sodium–Glucose Cotransporter 2 (SGLT2) Inhibitors on Arterial Stiffness and Vascular Aging—What Do We Know So Far? (A Narrative Review). Life 2022, 12, 803. https://doi.org/10.3390/life12060803

AMA Style

Adam CA, Anghel R, Marcu DTM, Mitu O, Roca M, Mitu F. Impact of Sodium–Glucose Cotransporter 2 (SGLT2) Inhibitors on Arterial Stiffness and Vascular Aging—What Do We Know So Far? (A Narrative Review). Life. 2022; 12(6):803. https://doi.org/10.3390/life12060803

Chicago/Turabian Style

Adam, Cristina Andreea, Razvan Anghel, Dragos Traian Marius Marcu, Ovidiu Mitu, Mihai Roca, and Florin Mitu. 2022. "Impact of Sodium–Glucose Cotransporter 2 (SGLT2) Inhibitors on Arterial Stiffness and Vascular Aging—What Do We Know So Far? (A Narrative Review)" Life 12, no. 6: 803. https://doi.org/10.3390/life12060803

APA Style

Adam, C. A., Anghel, R., Marcu, D. T. M., Mitu, O., Roca, M., & Mitu, F. (2022). Impact of Sodium–Glucose Cotransporter 2 (SGLT2) Inhibitors on Arterial Stiffness and Vascular Aging—What Do We Know So Far? (A Narrative Review). Life, 12(6), 803. https://doi.org/10.3390/life12060803

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Menu

Impact of Sodium–Glucose Cotransporter 2 (SGLT2) Inhibitors on Arterial Stiffness and Vascular Aging—What Do We Know So Far? (A Narrative Review)

Abstract

Share and Cite

Article Metrics

Article Access Statistics

Further Information

Guidelines

MDPI Initiatives

Follow MDPI